- Altendorf T, Gering I, Santiago-Schübel B, Aghabashlou Saisan S, Tamgüney G, Tusche M, Honold D, Schemmert S, Hoyer W, Mohrlüder J, Willbold D
Stabilization of monomeric Tau protein by all D-enantiomeric peptide ligands as therapeutic strategy for Alzheimer's disease and other tauopathies
Int J Mol Sci 24, 2161 (2023)
https://doi.org/10.3390/ijms24032161
- König AS, Rösener NS, Gremer L, Tusche M, Flender D, Reinartz E, Hoyer W, Neudecker P, Willbold D, Heise H
Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy
J Biol Chem 296, 100499 (2021)
https://doi.org/10.1016/j.jbc.2021.100499
- Elfgen A, Santiago-Schübel B, Hupert M, Schemmert S, Schartmann E, Tusche M, Gering I, Zafiu C, Kutzsche J.
Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid
Eur J Pharm Sci. , (2020)
https://pubmed.ncbi.nlm.nih.gov/33035662/
- Elfgen A, Hupert M, Bochinsky K, Tusche M, González de San Román Martin E, Gering I, Sacchi S, Pollegioni L, Huesgen PF, Hartmann R, Santiago-Schübel B, Kutzsche J, Willbold D.
Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
Sci Rep 9(1), 5715 (2019)
http://10.1038/s41598-019-41993-6
https://www.nature.com/articles/s41598-019-41993-6
- Dunkelmann T, Teichmann K, Ziehm T, Schemmert S, Frenzel D, Tusche M, Dammers C, Jürgens D, Langen KJ, Demuth HU, Shah NJ, Kutzsche J, Willuweit A, Willbold D
Aβ oligomer eliminating compounds interfere successfully with pEAβ (3–42) induced motor neurodegenerative phenotype in transgenic mice
Neuropeptides 67, 27-35 (2018)
https://doi.org/10.1016/j.npep.2017.11.011
https://www.sciencedirect.com/science/article/pii/S0143417917301531
- Schartmann E, Schemmert S, Niemietz N, Honold D, Ziehm T, Tusche M, Elfgen A, Gering I, Brener O, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A.
In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease.
J Alzheimers Dis 64(3), 859-873 (2018)
https://10.3233/JAD-180165
https://www.ncbi.nlm.nih.gov/pubmed/29966196
- Boeske A, Schwarten M, Ma P, Tusche M, Mötter J, Möller C, Neudecker P, Hoffmann S, Willbold D
Direct binding to GABARAP family members is essential for HIV-1 Nef plasma membrane localization
Scientific Reports 7, 5979 (2017)
- Gremer L, Schölzel D, Schenk C, Reinartz E, Labahn J, Ravelli RB, Tusche M, Lopez-Iglesias C, Hoyer W, Heise H, Willbold D, Schröder GF
Fibril structure of amyloid-ß(1-42) by cryoelectron microscopy
Science 358, 116-119 (2017)
http://dx.doi.org/10.1126/science.aao2825
http://science.sciencemag.org/content/early/2017/09/06/science.aao2825
- Klein AN, Ziehm T, van Groen T, Kadish I, Elfgen A, Tusche M, Thomaier M, Reiss K, Brener O, Gremer L, Kutzsche J, Willbold D
Optimization of D-peptides for Aβ monomer binding specificity enhances their potential to eliminate toxic Aβ oligomers
ACS Chem Neurosci 8, 1889-1900 (2017)
- Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D.
Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.
Molecules 22(10), (2017)
http://10.3390/molecules22101693
https://www.ncbi.nlm.nih.gov/pubmed/28994710
- Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A.
Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.
Eur J Pharm Sci. 17, 0928-0987 (2017)
https://doi.org/10.1016/j.ejps.2017.12.005
https://www.ncbi.nlm.nih.gov/pubmed/29225107
- van Groen T, Schemmert S, Brener O, Gremer L, Ziehm T, Tusche M, Nagel-Steger L, Kadish I, Schartmann E, Elfgen A, Jürgens D, Willuweit A, Kutzsche J, Willbold D.
The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.
Sci Rep. 7, 16275 (2017)
https://doi.org/10.1038/s41598-017-16565-1
https://www.nature.com/articles/s41598-017-16565-1
- Klein AN, Ziehm T, Tusche M, Buitenhuis J, Bartnik D, Boeddrich A, Wiglenda T, Wanker E, Funke SA, Brener O, Gremer L, Kutzsche J, Willbold D.
Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination.
PLoS One 11(4), (2016)
http://dx.doi.org/10.1371/journal.pone.0153035
Erratum in: PLoS One. 2016;11(7):e0158960. http://dx.doi.org/10.1371/journal.pone.0158960
- Rudolph S, Klein AN, Tusche M, Schlosser C, Elfgen A, Brener O, Teunissen C,Gremer L, Funke SA, Kutzsche J, Willbold D.
Correction: Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity
PLoS One 11(7), (2016)
http://dx.doi.org/10.1371/journal.pone.0159470
http://journals.plos.org/plosone/article?id=info:doi/10.1371/journal.pone.0159470
- Rudolph S, Klein AN, Tusche M, Schlosser C, Elfgen A, Brener O, Teunissen C, Gremer L, Funke SA, Kutzsche J, Willbold D.
Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity.
PLoS One 11(2):e0147470., (2016)
http://dx.doi.org/10.1371/journal.pone.0147470
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147470
- Ziehm T, Brener O, van Groen T, Kadish I, Frenzel D, Tusche M, Kutzsche J, Reiß K, Gremer L, Nagel-Steger L, Willbold D.
Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species.
ACS Chem Neurosci. 7 (8), 1088–1096 (2016)
http://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00047
- Brener O, Dunkelmann T, Gremer L, van Groen T, Mirecka EA, Kadish I, Willuweit A, Kutzsche J, Jürgens D, Rudolph S, Tusche M, Bongen P, Pietruszka J, Oesterhelt F, Langen K-J, Demuth H-U, Janssen A, Hoyer W, Funke SA, Nagel-Steger L, Willbold D
QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
Sci Rep 5, 13222 (2015)
http://dx.doi.org/10.1038/srep13222
Responsible for the content: